Roivant reports Phase 2b lupus failure for an FcRn drug
One of Roivant's leading autoimmune pipeline candidates failed a Phase 2b study in a form of lupus, the company said Wednesday morning.
Roivant Sciences
Clinical-stage biopharmaceutical company that builds and launches modular subsidiary companies (Vants) developing transformative therapies across immunology, neurology, oncology, and rare disease.
Company Info
Upcoming Milestones & Key Dates
2026-Q4
Clinical
IMVT-1402 Phase 3 readouts expected
2027-Q1
Clinical
RVT-3101 UC Phase 3 data expected
Clinical Development Pipeline
IMVT-1402
Target: FcRn antibodyRVT-3101
Target: Anti-TL1ABrepocitinib
Target: TYK2/JAK1Recent News
Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off
Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off
Roivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data
Roivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data — latest biotech and pharma news.
Leadership Team
Matt Gline
Chief Executive Officer
Eric Venker
President & Chief Operating Officer
Richard Pulik
Chief Financial Officer